Vasculitic neuropathies

Comana M Cioroiu MD (Dr. Cioroiu of Columbia University has no relevant financial relationships to disclose.)
Louis H Weimer MD, editor. (Dr. Weimer of Columbia University has received consulting fees from Roche.)
Originally released December 23, 1994; last updated July 20, 2016; expires July 20, 2019

This article includes discussion of vasculitic neuropathies, angiitis, arteritis, necrotizing angiitis, necrotizing arteritis, and necrotizing vasculitis. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

The vasculitides are a group of heterogeneous disorders that present with a variable and complex clinical picture. Debates over clinical versus pathological approaches to classification abound in the literature, all with recognized limitations given the variable clinical presentations and the overlap between the recognized diagnostic entities. Peripheral neuropathy is an important, and often the presenting, clinical feature of the vasculitides. Its recognition can be critical to attain an early diagnosis in these disorders where the ultimate outcome can be greatly influenced by early therapeutic intervention.

Key points

 

• Neuropathy related to vasculitis can occur as either a primary condition (in the setting of systemic vasculitis) or secondary to a range of diseases including infection and connective tissue disorders. Localized nonsystemic vasculitic neuropathies include diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and nondiabetic lumbosacral radiculoplexus neuropathy (LRPN).

 

• Vasculitic neuropathies can be classified according to clinical features or histopathologically based on the size of involved vessels.

 

• Diagnostic tests include electrodiagnostic studies demonstrating an asymmetric non-length dependent axonal neuropathy and nerve biopsy when necessary.

 

• Management involves institution of immunosuppressive therapy and removal of the inciting agent when present.

Historical note and terminology

Peripheral neuropathy figured prominently in the first complete description of a systemic necrotizing vasculitis (polyarteritis nodosa) by Kussmaul and Maier in 1866. For the next 80 years, essentially all vasculitic diseases, irrespective of clinical features, were called polyarteritis nodosa. Scattered descriptions of patients with peripheral neuropathy appeared in many of these early reports. Neuropathy occurring in the setting of rheumatoid arthritis was also described in the late 19th century, and one report described in detail the vascular histopathology (Chalk et al 1993a).

In the 1950s, hypersensitivity vasculitis, Churg-Strauss syndrome, and Wegener granulomatosis were all described in the English language literature as entities distinct from polyarteritis nodosa, and Zeek first proposed a classification scheme for the vasculitic syndromes based on the size of involved blood vessels (Alpern 1995). Over the next 20 years, numerous reports appeared detailing the clinical features, histopathology, response to treatment, and prognosis of the various vasculitic syndromes; peripheral neuropathy was an important finding in many of these reports. During this time several different, and often conflicting, classification schemes for the vasculitides were proposed based on the size of involved vessels, type of vascular pathology, clinical features, or immunopathologic mechanisms. Despite several multicenter studies that have attempted to standardize the nomenclature, diagnostic criteria, and classification of the vasculitic syndromes, some confusion over these issues persists (Hunder et al 1990; Jennette et al 1994; Alpern 1995). The International Chapel Hill Consensus Conference updated their classification system in 2012, now organized primarily by vessel size and etiology (Jennette et al 2013a). Additionally, in 2010, the Peripheral Nerve Society published new guidelines on the classification of vasculitic neuropathies, subdividing them into primary systemic, secondary systemic, and nonsystemic or localized vasculitides. This scheme included the entities of nondiabetic lumbar radiculoplexus neuropathy (LRPN) and diabetic lumbosacral radiculoplexus neuropathy (DLRPN), which had not been included in prior classification systems (Collins et al 2010).

In 1972, Dyck and colleagues published a seminal work detailing the sural nerve histopathology in 14 patients with various vasculitic syndromes (Dyck et al 1972). This study correlated the three-dimensional morphology of nerve fiber degeneration and vascular pathology, and provided strong support for the concept that ischemia probably accounts for the nerve damage in these syndromes. Several large series of patients with vasculitic neuropathy have defined the clinical spectrum, laboratory features, electrophysiologic findings, and immunopathology of these syndromes. An important concept to emerge from these studies is that neuropathy can be the sole manifestation of an underlying vasculitis (Kissel et al 1985; Bouche et al 1986; Harati and Niakan 1986; Dyck et al 1987; Said et al 1988; Panegyres et al 1990; Hawke et al 1991; Nicolai et al 1995; Davies et al 1996). Several studies have documented a true necrotizing vasculitis associated with the syndrome of proximal diabetic neuropathy (diabetic amyotrophy/lumbosacral radiculoplexus neuropathy) (Krendel 1998; Dyck 1999; Griffin 2003; Said 2003). A similar vasculopathy has also been found in nondiabetics presenting with lumbosacral radiculoplexopathy (Dyck 2001).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.